Figure 1.

Patient-derived organoids (PDOs) as a personalized aging tool. PDOs can be obtained from reprogramming adult stem cells into uncommitted induced pluripotent stem cells (iPSCs), which through a series of differentiation steps result in the generation of the desired tissue type organoid. Alternatively, tumor resection or liquid biopsy/circulating-tumor cells (CTC) can be the source of the adult stem cell (ASCs) required to establish the organoid. Modeling aging with PDOs have a tremendous potential as a preclinical model tool to discover new biomarkers of aging, to predict adverse outcomes during aging, and to design personalized approaches for prevention and treatment of aging-related diseases and geriatric syndromes. This could represent a novel approach to study chronological and/or biological aging, paving the way to personalized interventions targeting the biology of aging.